Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma

JAMA Oncology

Volumn 2, Issue 8, 2016, Pages 1094-1096

  Liu, David ^a   Plimack, Elizabeth R ^b   Hoffman Censits, Jean ^d   Garraway, Levi A ^a,c   Bellmunt, Joaquim ^a   Allen, Eliezer Van ^a,c   Rosenberg, Jonathan E ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERCC2 PROTEIN, HUMAN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

CARCINOMA, TRANSITIONAL CELL; COHORT ANALYSIS; GENETICS; HUMAN; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; SMOOTH MUSCLE; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VALIDATION STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; HUMANS; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 85016513285     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.1056     Document Type: Letter

References (2)

1. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer [published online April 7, 2016]. JAMA Oncol. doi:10.1001/jamaoncol .2016.0173.
2. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc. 2015;90(10):1440-1454.